Intangible Assets

NOEMR’s negative TTM ROIC and ROCE indicate it is not converting any presumed brand, IP, or regulatory advantages into durable excess returns versus peers.

The absence of disclosed 5-year margin and return history in the provided metrics limits evidence that any intangible asset base is sustaining pricing power over time.

With no visible profitability premium, any customer recognition or proprietary know-how appears insufficient to create a durable moat relative to stronger peers.

Compared with peers that can demonstrate positive and persistent returns on capital, NOEMR currently looks like a business without proven intangible-driven differentiation.

Switching Costs

The provided metrics do not show retention, renewal, or embedded-workflow evidence, so there is no support for meaningful customer lock-in versus peers.

Negative returns on capital suggest customers are not dependent on NOEMR in a way that preserves pricing power or prevents substitution.

Without evidence of integration depth or contractual stickiness, switching costs appear low and likely weaker than peers with recurring, mission-critical usage.

The current data imply customers can replace NOEMR with limited friction, which undermines moat durability.

Network Effects

The supplied metrics contain no signs of user growth, ecosystem participation, or cross-side adoption that would indicate a self-reinforcing network effect.

Negative ROIC and ROCE argue against a platform dynamic where scale is translating into stronger monetization than peers.

There is no evidence that more users, transactions, or data are making the product more valuable for existing customers.

Relative to peers with observable ecosystem pull, NOEMR shows no demonstrated network advantage.

Cost Advantage

Negative TTM ROIC and ROCE indicate NOEMR is not operating with a cost structure that produces superior unit economics versus peers.

The zero cash conversion cycle and zero asset turnover in the provided data do not support evidence of operating efficiency that would sustain a cost edge.

Without margin history or scale-driven productivity evidence, there is no basis to conclude NOEMR can underprice peers while preserving returns.

Compared with lower-cost competitors, NOEMR currently lacks proof of a durable cost advantage.

Efficient Scale

The available metrics do not show that NOEMR operates in a niche where limited market size protects returns from competition.

Negative capital returns suggest scale is not yet creating a protected position that deters entry or preserves economics versus peers.

There is no evidence of capacity constraints, regulated scarcity, or dominant share that would make the market naturally support efficient scale.

Relative to peers with clear local or regulatory scale barriers, NOEMR does not exhibit efficient-scale protection.

Overall Score

NOEMR shows no demonstrated structural moat in the provided data, as negative capital returns and missing long-term operating evidence point to weak pricing power, low retention, and no clear peer-relative advantage across the five moat drivers.